Privacyvoorkeur

MEDtalks houdt u graag op de hoogte van de laatste ontwikkelingen op uw interessegebied. Kies hieronder of u op de hoogte gehouden wilt blijven van de nieuwste programma's en nascholingen binnen uw interessegebieden. Klik hier voor meer informatie.

Aftertalk: Congresupdate GI kanker 2025

Direct na de congresupdate gastro-intestinale kanker 2025, vers van het dagprogramma, gingen internist-oncologen Jeanine Roodhart, Laurens Beerepoot en Maartje Los van de programmacommissie in gesprek over de belangrijkste inzichten en de mogelijke implicaties voor de praktijk die zij presenteerden op het event in Sint-Michielsgestel waar Nederlandse en Vlaamse artsen bijeen kwamen.

Zij bespreken de onderstaande studies, waarbij de links u direct naar het ASCO GI-abstract leiden.

Maag- en oesofaguscarcinoom

Preliminary results from the multicenter, randomized phase III trial (SCIENCE): Comparing chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant treatment in resectable locally advanced esophageal squamous cell carcinoma.

Integrating Local With Systemic Therapies for Esophagus and Gastroesophageal Junction Cancers. Post-ESOPEC: Where Does Radiotherapy Fit?

Neuro-endocrien - hepatocellulair - en pancreascarcinoom

LAPIS Randomized phase 3 trial of chemotherapy (CTX) with and without pamrevlumab (PAM) for locally advanced pancreatic cancer (LAPC).

Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP) Bayesian platform trial.

Effect of baseline geriatric and quality of life assessments on treatment outcomes in ECOG-ACRIN EA2186 (GIANT): A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer.

Adjuvant chemotherapy or chemo-radiation in gallbladder cancer: A phase III randomized controlled study (ACCELERATE trial).

Colorectaal carcinoom

First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW

BREAKWATER: Analysis of first-line encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant metastatic colorectal cancer.